Are circulating CC10 levels and gene G38A polymorphism associated with subsequent asthma outcomes in patients with moderate-to-severe asthma ?

<bold>Rationale:</bold> This study evaluates serum CC10 level variations during follow-up and the potential influence of the rs3741240 (G38A) gene polymorphism as predictors for outcomes in patients with moderate-to-severe asthma. <bold>Methods:</bold> Within the French COBRA cohort, adults diagnosed with asthma were prospectively followed every 6 months. CC10 levels were measured at each visit, and CC10 gene polymorphism rs3741240 (G38A) was assessed. Demographic, clinical, biological (eosinophilia), lung function data and outcomes (frequency of asthma symptoms, ACQ, exacerbations) were collected. <bold>Results:</bold> Moderate-to-severe asthma patients without any missing data over 5 consecutive visits (2.5 years, n=198) were included. Higher CC10 level at visit (n) was significantly associated with reduced reported asthma symptoms recorded at visit (n+1) (OR=0.914, 95% CI [0.838-0.997], p=0.043). However, CC10 levels failed to predict exacerbations, ACQ scores, hospitalizations, eosinophilia, or FEV1. Additionally, while the A/A genotype was consistently associated with lower CC10 levels over time, none of the CC10 polymorphisms (A/A, A/G, G/G) was associated with any asthma outcomes. <bold>Conclusion:</bold> Circulating CC10 level during follow-up is inversely related to symptom burden but not with exacerbations in moderate-to-severe asthma patients, reducing its potential role as a predictive biomarker